Filing Details

Accession Number:
0001628280-19-010912
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-08-16 20:33:39
Reporting Period:
2019-08-14
Accepted Time:
2019-08-16 20:33:39
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1576280 Guardant Health Inc. GH Services-Medical Laboratories (8071) 454139254
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1753789 J Michael Wiley 505 Penobscot Drive
Redwood City CA 94063
Chief Legal Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-08-16 30,000 $4.18 261,737 No 4 M Direct
Common Stock Disposition 2019-08-16 51,976 $100.82 209,761 No 4 S Direct
Common Stock Disposition 2019-08-16 1,024 $101.55 208,737 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock STOCK OPTION (RIGHT TO BUY) Disposition 2019-08-16 30,000 $0.00 30,000 $4.18
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
117,560 2027-07-13 No 4 M Direct
Footnotes
  1. Some of these shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Some of the shares sold were acquired contemporaneously upon the cashless exercise of stock options at an exercise price of $4.18 per share.
  2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $100.50 to $101.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities andExchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $101.51 to $101.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities andExchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on April 23, 2017.